TABLE 3.

Patient Characteristics Compared by Remission Status Within 12 Months After Ustekinumab Dose Intensification

Characteristic	No Corticosteroid-free Remission (n = 34)	Corticosteroid-free Remissiona (n = 42)	P b
Age, mean y	42.0	42.7	0.82
Sex, %			0.43
Female	52.9	61.9
Male	47.1	38.1
Race, %			0.31
Asian	0.0	2.4
Black	0.0	7.1
Hispanic	2.9	0.0
Unknown	2.9	4.8
White	94.1	85.7
Age of IBD diagnosis, mean, y	26.0	26.1	0.97
Disease duration at ustekinumab start, mean, y	15.0	14.5	0.80
Time on ustekinumab before intensification, mean, d	347.6	345.1	0.97
Ustekinumab level before intensification, mean, ug/mL, n = 2, n = 5	3.9	2.4	0.63
Current smoking, %	14.7	7.1	0.29
Current cannabis, %	26.5	14.3	0.18
Current opioids, %	50.0	21.4	<0.01
Intensification frequency, %			0.66
q4 weeks	55.9	54.8
q5 weeks	0.0	0.0
q6 weeks	44.1	42.9
q7 weeks	0.0	2.4
HBI within 3 months before intensification, %, n = 33, n = 37			0.02
Remission (<5)	0.0	13.5
Mild (5–7)	30.3	46.0
Moderate (8–16)	63.6	40.5
Severe (>16)	6.1	0.0
Extraintestinal manifestations, %	61.8	54.8	0.54
Prior IBD surgery, %	70.6	50.0	0.07
Prior anti-TNF, %	100.0	100.0	n/a
>1 prior anti-TNF, %	79.4	73.8	0.57
Prior anti-integrin, %	50.0	47.6	0.84
Current corticosteroids, %	29.4	28.6	0.94
CD Location (Montreal classification), %			0.41
L1 Terminal ileum	5.9	1.9
L2 Colon	23.5	26.2
L3 Ileocolon	67.6	57.1
L4 Upper GI	2.9	0.0
L3+L4 Ileocolon + Upper GI	0.0	4.8
CD Behavior (Montreal classification), %			0.83
B1 Nonstricturing, nonpenetrating	26.5	26.2
B2 Stricturing	11.8	16.7
B3 Penetrating	61.8	57.1
Perianal disease, %	58.8	33.3	0.03
Lab markers within 3 months before intensification
Fecal calprotectin >120 mcg/g, %, n = 9, n = 12	64.3	85.7	0.19
Albumin to CRP ratio, mean, n = 30, n = 36	217.1	137.9	0.55

^aExcludes patients with both HBI <5 and no use of corticosteroids at time of intensification

^bCalculated by Student t test or Pearson χ ² test